ARCHIVES

Risk-Benefit Analysis Advised Prior To Hormone Therapy

This article is from The Cancer Letter archive.

Vol. 33 No. 8 | August 27, 2010

Download PDF Visit The Full Archive

Related Articles

Three-Quarters of P01 $$ Goes To Translational Grants, NCI Finds

October 2, 1992

EGFR Inhibitor Shrinks Tumors In Phase I Study of Patients With Treatment-Resistant Mutation

May 30, 2014

Patients Report Clinical Trials Not Offered By Physician

June 27, 2008

Univ. Of Pittsburg Vows To Make Changes To Keep NSABP

April 8, 1994

NCI Reorganization Task Forces Near Decisions On New Division’s Makeup; Terry May Be Canidate

May 25, 1979

Female Smokers Face Double Risk For Lung Cancer

July 28, 2006